.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average consequence of 11 months, individuals along with metastatic gastrointestinal growths who acquired biomarker-matched therapies based on spreading lump DNA profiling showed a better scientific advantage than those obtaining unequaled therapy.